These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37814378)

  • 41. Liver microphysiological systems development guidelines for safety risk assessment in the pharmaceutical industry.
    Baudy AR; Otieno MA; Hewitt P; Gan J; Roth A; Keller D; Sura R; Van Vleet TR; Proctor WR
    Lab Chip; 2020 Jan; 20(2):215-225. PubMed ID: 31799979
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gastrointestinal microphysiological systems.
    Blutt SE; Broughman JR; Zou W; Zeng XL; Karandikar UC; In J; Zachos NC; Kovbasnjuk O; Donowitz M; Estes MK
    Exp Biol Med (Maywood); 2017 Oct; 242(16):1633-1642. PubMed ID: 28534432
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Opportunities and Challenges of Disease Progression Modeling in Drug Development - An IQ Perspective.
    Goteti K; Hanan N; Magee M; Wojciechowski J; Mensing S; Lalovic B; Hang Y; Solms A; Singh I; Singh R; Rieger TR; Jin JY
    Clin Pharmacol Ther; 2023 Aug; 114(2):266-274. PubMed ID: 36802040
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop.
    Romero K; Sinha V; Allerheiligen S; Danhof M; Pinheiro J; Kruhlak N; Wang Y; Wang SJ; Sauer JM; Marier JF; Corrigan B; Rogers J; Lambers Heerspink HJ; Gumbo T; Vis P; Watkins P; Morrison T; Gillespie W; Gordon MF; Stephenson D; Hanna D; Pfister M; Lalonde R; Colatsky T
    J Pharmacokinet Pharmacodyn; 2014 Dec; 41(6):545-52. PubMed ID: 25288257
    [TBL] [Abstract][Full Text] [Related]  

  • 46. International Conference on Harmonisation; guidance on Q10 Pharmaceutical Quality System; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Apr; 74(66):15990-1. PubMed ID: 19507321
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control.
    Hariparsad N; Ramsden D; Palamanda J; Dekeyser JG; Fahmi OA; Kenny JR; Einolf H; Mohutsky M; Pardon M; Siu YA; Chen L; Sinz M; Jones B; Walsky R; Dallas S; Balani SK; Zhang G; Buckley D; Tweedie D
    Drug Metab Dispos; 2017 Oct; 45(10):1049-1059. PubMed ID: 28646080
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Microphysiological systems for ADME-related applications: current status and recommendations for system development and characterization.
    Fowler S; Chen WLK; Duignan DB; Gupta A; Hariparsad N; Kenny JR; Lai WG; Liras J; Phillips JA; Gan J
    Lab Chip; 2020 Feb; 20(3):446-467. PubMed ID: 31932816
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop.
    Lesko LJ; Salerno RA; Spear BB; Anderson DC; Anderson T; Brazell C; Collins J; Dorner A; Essayan D; Gomez-Mancilla B; Hackett J; Huang SM; Ide S; Killinger J; Leighton J; Mansfield E; Meyer R; Ryan SG; Schmith V; Shaw P; Sistare F; Watson M; Worobec A
    J Clin Pharmacol; 2003 Apr; 43(4):342-58. PubMed ID: 12723455
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Proceedings of the Second Workshop on Theory meets Industry (Erwin-Schrödinger-Institute (ESI), Vienna, Austria, 12-14 June 2007).
    Hafner J
    J Phys Condens Matter; 2008 Feb; 20(6):060301. PubMed ID: 21693862
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Developing interdisciplinary maternity services policy in Canada. Evaluation of a consensus workshop.
    Martin CM; Kasperski J
    J Eval Clin Pract; 2010 Feb; 16(1):238-45. PubMed ID: 20367842
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Development of Microphysiological Systems (MPSs) Based on Microfluidic Technology for Drug Discovery in Japan].
    Kimura H
    Yakugaku Zasshi; 2023; 143(1):39-44. PubMed ID: 36596538
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recommended Guidelines for Developing, Qualifying, and Implementing Complex In Vitro Models (CIVMs) for Drug Discovery.
    Ekert JE; Deakyne J; Pribul-Allen P; Terry R; Schofield C; Jeong CG; Storey J; Mohamet L; Francis J; Naidoo A; Amador A; Klein JL; Rowan W
    SLAS Discov; 2020 Dec; 25(10):1174-1190. PubMed ID: 32495689
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Equivalence considerations for orally inhaled products for local action-ISAM/IPAC-RS European Workshop report.
    Evans C; Cipolla D; Chesworth T; Agurell E; Ahrens R; Conner D; Dissanayake S; Dolovich M; Doub W; Fuglsang A; García Arieta A; Golden M; Hermann R; Hochhaus G; Holmes S; Lafferty P; Lyapustina S; Nair P; O'Connor D; Parkins D; Peterson I; Reisner C; Sandell D; Singh GJ; Weda M; Watson P
    J Aerosol Med Pulm Drug Deliv; 2012 Jun; 25(3):117-39. PubMed ID: 22413806
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PDA Biosimilars Workshop Report (September 27-28, 2018)-Getting It Right the First Time for Biosimilar Marketing Applications.
    Krause S; Lacana E; Welch J; Shapiro M; Downey C; Chung J; Zhou Q; Van Der Plas M; Depatie C; Ingram B; Srebalus-Barnes C; Polozova A; Rellahan B; Choi D; Burdick R; Stangler T; Shacter E
    PDA J Pharm Sci Technol; 2019; 73(4):401-416. PubMed ID: 31004040
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Qualitative Value of Facilitated Regulatory Pathways in Europe, USA, and Japan: Benefits, Barriers to Utilization, and Suggested Solutions.
    Bujar M; McAuslane N; Liberti L
    Pharmaceut Med; 2021 Mar; 35(2):113-122. PubMed ID: 33537899
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enabling pharmacogenomic clinical trials through sampling.
    Warner A; Nelsen A; Bhathena A; Fitzgerald K; Gilardi S; Kelso E; Knoppers B; McLeod HL; Nelson R; Uyama Y; Weisman J; Rudman A
    Pharmacogenomics; 2010 Dec; 11(12):1649-54. PubMed ID: 21142907
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro exposure systems and dosimetry assessment tools for inhaled tobacco products: Workshop proceedings, conclusions and paths forward for in vitro model use.
    Behrsing H; Hill E; Raabe H; Tice R; Fitzpatrick S; Devlin R; Pinkerton K; Oberdörster G; Wright C; Wieczorek R; Aufderheide M; Steiner S; Krebs T; Asgharian B; Corley R; Oldham M; Adamson J; Li X; Rahman I; Grego S; Chu PH; McCullough S; Curren R
    Altern Lab Anim; 2017 Jul; 45(3):117-158. PubMed ID: 28816053
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Global Bioequivalence Harmonization Initiative: Summary report for EUFEPS international conference.
    Chen ML; Blume H; Beuerle G; Davit B; Mehta M; Potthast H; Schug B; Tsang YC; Wedemeyer RS; Weitschies W; Welink J
    Eur J Pharm Sci; 2018 Jan; 111():153-157. PubMed ID: 28964950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.